Molecular Partners' Ensovibep Shows Early Safety Profile In COVID-19

Molecular Partners AG MOLN announced the presentation of results from the Phase 2a study of ensovibep for COVID-19 patients and additional data from the Phase 1 study in healthy volunteers at the virtual European Scientific Working Group on Influenza (ESWI) Conference.
The single-arm Phase 2a study enrolled 12 patients with mild to moderate COVID-19 symptoms.
First ensovibep data from COVID-19 infected patients at 225 mg and 600 mg doses were seen to be safe and well-tolerated.
No disease enhancement, related infusion reactions, or dose-limiting toxicities were observed.
Viral load data (qPCR) showed a comparable decline for both dose levels.
Infectivity of virus extracted through nasopharyngeal swabs was reduced to zero within 3-5 days post-treatment in patients with positive titers at baseline.
Related Link: See Why Molecular Partners Shares Dropped To 52-Week Low During Tuesday Premarket?
Global Phase 2/3 EMPATHY trial for ambulatory COVID-19 patients is ongoing, with topline data available in early 2022.
Molecular Partners also presented additional data from the Phase 1 study of intravenously administered ensovibep, which indicated that it was well tolerated with a half-life in the range of 2-3 weeks.
Price Action: MOLN shares closed lower by 1.91% at $13.35 on Friday.